<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02871011</url>
  </required_header>
  <id_info>
    <org_study_id>SAN-CPT-01</org_study_id>
    <nct_id>NCT02871011</nct_id>
  </id_info>
  <brief_title>Nitric Oxide Releasing Solution (NORS) Footbath to Treat Athlete's Foot</brief_title>
  <official_title>A Blinded Placebo Controlled Clinical Trial To Evaluate Fungicidal Activity With The Topical Application Of Nitric Oxide Releasing Solution (Nors) In Subjects With Moderate To Severe Tinea Pedis (Athlete's Foot)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nitric Solutions Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nitric Solutions Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the fungicidal efficacy of nitric oxide releasing
      solution footbath and it's effect on the clinical signs and symptoms associated with Tinea
      Pedis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Type: Interventional Study Design: Allocation: Randomized Endpoint Classification:
      Efficacy Study Intervention Model: Sequential Assignment Masking: Double Blind (Subject &amp;
      Assessor) Primary Purpose: Treatment
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evidence of fungicidal activity as confirmed by mycological culture or microscopic evaluation and improvement in Clinical Symptom Severity Score</measure>
    <time_frame>Day 17 or Day 31</time_frame>
    <description>The primary efficacy endpoint for this study is to quantify mycological response post NORS treatment applications. Complete cure will be determined by negative fungal culture or negative microscopic evaluation via KOH preparation and a Clinical Symptom Severity Score of ≤ 8.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Duration of the study, 31 days for each participant.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Tinea Pedis</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Water, delivered as a footbath for 30 minutes, daily for 3 consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nitric oxide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nitric oxide delivered as a footbath for 30 minutes, daily for 3 consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitric Oxide</intervention_name>
    <description>Delivered as a footbath</description>
    <arm_group_label>Nitric oxide</arm_group_label>
    <other_name>NORS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Water</intervention_name>
    <description>Delivered as a footbath</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive clinical findings for moccasin, interdigital or bullous tinea pedis as
             determined by direct clinical examination

          -  Must have a clinical symptom severity score of at least 20 on a possible 64 point
             scale

          -  Written informed consent must be obtained from the subject.

          -  Must ≥ 19 years of age, for study sites located in British Columbia. For other
             locations the subject must be ≥ 18 years of age, unless local laws dictate otherwise.

          -  Must agree to avoid professional pedicures or application of any nail polish product
             or nail cosmetic to the toenails after the screening visit until the conclusion of the
             trial.

          -  Must agree to take measures to avoid pregnancy during the 31 day study period

        Exclusion Criteria:

          -  Has a diagnosis of either psoriasis or eczema, in or immediately around the area under
             evaluation.

          -  Has a visual diagnosis, by the investigator, of onychomycosis at a level, which in the
             opinion of the investigator could compromise the integrity of the study.

          -  Use of topical antifungals e.g. (clotrimazole, ketoconazole,miconazole, oxiconazole-
             (Oxistat®, Glaxo Smith Kline), sulconazole, naftifine (Naftin®, Merz), terconazole,
             econazole nitrate (Spectazole®, Ortho-McNeil), butoconazole ,Fluconazole, ciclopirox
             olamine-(Loprox®, Medicis), tolnaftate, haloprogin), Zeasorb-AF , antibacterials and
             corticosteroids in the preceding 5 days of screening visit (Day 1) on or immediately
             around the area under evaluation.

          -  Use of systemic corticosteroids in the preceding 7 days respectively, of screening
             visit (Day 1)

          -  Use of systemic antifungals in the preceding 7 days of screening visit (Day1)
             including - (terbinafine - (Lamisil®, Novartis), Itraconazole - (Sporanox®, Janssen),
             fluconazole- (Diflucan®, Pfizer), ketoconazole, miconazole, griseofulvin (Gris-PEG®,
             Pedinol), butoconazole, terconazole, Potassium iodide)

          -  Has used any investigational drug(s) within 30 days preceding screening visit (Day 1)

          -  Is pregnant or is a nursing mother

          -  Is a woman of child bearing potential who is not using an adequate form of
             contraception (or abstinence)

          -  Is &lt; 19 years of age, for study sites located in British Columbia. For other locations
             subject is &lt; 18 years of age, unless local laws dictate otherwise.

          -  Suffers from a condition, which, in the opinion of the medical investigator, would
             compromise his/her safety and / or the quality of the data. Such conditions may
             include collagen vascular disease, diabetes mellitus, Cushing's Disease, hematological
             malignancy, chronic mucocutaneous candidiasis or atopy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Miller, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nitric Solutions Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Minna K Miller, DNP</last_name>
    <phone>604-442-3871</phone>
    <email>minna@nitricsolutions.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fairmont Medical Clinic</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z-16H</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minna K Miller, DNP</last_name>
      <phone>604-442-3871</phone>
      <email>minna@nitricsolutions.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2016</study_first_submitted>
  <study_first_submitted_qc>August 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2016</study_first_posted>
  <last_update_submitted>August 12, 2016</last_update_submitted>
  <last_update_submitted_qc>August 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tinea Bronchodilator Agents</keyword>
  <keyword>Tinea Pedis</keyword>
  <keyword>Nitric Oxide</keyword>
  <keyword>Dermatomycoses</keyword>
  <keyword>Endothelium-Dependent Relaxing Factors</keyword>
  <keyword>Infectious</keyword>
  <keyword>Infection</keyword>
  <keyword>Mycoses</keyword>
  <keyword>Skin Diseases</keyword>
  <keyword>Foot Dermatoses</keyword>
  <keyword>Foot Diseases</keyword>
  <keyword>Pruritus</keyword>
  <keyword>Skin Manifestations Signs and Symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinea</mesh_term>
    <mesh_term>Tinea Pedis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
    <mesh_term>Endothelium-Dependent Relaxing Factors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

